References are provided within the modular chunk itself to facilitate quick review. Additionally, this format will facilitate seamless updating of guidelines with focused updates as new evidence is published, as well as content tag- ging for rapid electronic retrieval of related recommendations on a topic of interest. This evolved approach format was insti- tuted when this guideline was near completion; therefore, the present document represents a transitional format that best suits the text as written. Future guidelines will fully implement this format, including provisions for limiting the amount of text in a guideline. Recognizing the importance of cost value considerations in certain guidelines, when appropriate and feasible, an analy- sis of the value of a drug, device, or intervention may be per- formed in accordance with the ACC/AHA methodology.P-5 To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guide- line revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or man- agement strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manualP-6 and other methodology Selection of Writing Committee Members The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, eth- nicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite orga- nizations and professional societies with related inter- ests and expertise to participate as partners, collaborators, or endorsers. 